Currently, seven antibodies targeting three major immune check point proteins (anti-CTLA4, anit-PD1 and anti-PDL1) have been approved by the FDA for the treatment of several different tumor entities, including KRASmut melanoma and non-small cell lung cancer [110]. Here, CTLA4 is linked to non-small cell lung carcinoma.